Related Experiment Videos
Pleuropulmonary fibrosis due to bromocriptine treatment for Parkinson's disease
D H Todman1, W A Oliver, R L Edwards
1Department of Neurology, Repatriation General Hospital, Brisbane.
Clinical and Experimental Neurology
|January 1, 1990
Abstract:
Pleuroplumonary fibrosis is an uncommon but potentially serious adverse effect of bromocriptine used in the treatment of Parkinson's disease. Two cases of this reaction, which occurred 12 months and 5 months respectively after commencing therapy are here reported. In both instances prompt clinical and radiological improvement occurred when bromocriptine intake was ceased. Fibrotic reactions to bromocriptine may be mediated by a serotonergic mechanism. Periodic monitoring of pulmonary symptoms is warranted in patients receiving bromocriptine treatment for Parkinson's disease.